Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC

Barclays PLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 181,591 shares of the company's stock after selling 40,798 shares during the quarter. Barclays PLC owned about 0.18% of Neurocrine Biosciences worth $20,922,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock valued at $1,574,000 after buying an additional 90 shares in the last quarter. Fifth Third Bancorp raised its position in Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company's stock valued at $99,000 after purchasing an additional 92 shares during the period. Total Clarity Wealth Management Inc. lifted its stake in shares of Neurocrine Biosciences by 4.3% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after purchasing an additional 100 shares during the last quarter. Commerce Bank boosted its holdings in shares of Neurocrine Biosciences by 2.6% in the 3rd quarter. Commerce Bank now owns 4,199 shares of the company's stock worth $484,000 after purchasing an additional 108 shares during the period. Finally, Caprock Group LLC increased its position in shares of Neurocrine Biosciences by 7.0% during the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company's stock valued at $230,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research note on Friday, October 4th. BMO Capital Markets cut their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a report on Thursday, October 17th. Raymond James reissued an "outperform" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $165.18.

Insider Transactions at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now owns 15,449 shares of the company's stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX traded down $0.09 during trading hours on Friday, reaching $126.70. The company's stock had a trading volume of 781,662 shares, compared to its average volume of 866,688. The stock has a 50 day moving average price of $121.75 and a two-hundred day moving average price of $130.62. The company has a market capitalization of $12.83 billion, a P/E ratio of 33.97 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.